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A Commentary on
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We thank Crezee et al. for their opinion article concerning the impact of the time interval
between radiotherapy (RT) and hyperthermia (HT), elicited by our recent publication showing no
effect of the time interval on clinical outcome (1). We welcome the discussion, as time interval
between RT and HT is one of the important issues to solve for the hyperthermia community
in the near future. As stated in our conclusion, several hyperthermia centers are centralized and
receive many patients from radiotherapy departments elsewhere. Also, from a patient perspective,
receiving a daily radiotherapy fraction nearby and only traveling to a more distant located
hyperthermia facility once a week is preferable and could increase acceptance and tolerance of the
thermoradiotherapy treatment.
We regret the feeling of insufficient caution in our conclusions. In fact, we and our referring
radiation oncologists took the results of the study of van Leeuwen very seriously. It initiated an
intense discussion as to whether the treatment procedure for RT+HT should be offered only if
both treatments could be delivered in the same institution to maintain a short treatment interval
between the therapies. After all, the international standard for locally advanced cervix cancer
consists of combined radiotherapy and platinum-based chemotherapy (2). However, there is a
gray zone for elderly patients or patients with larger tumors depending on the confidence in the
alternative of combined RT + HT and the regional availability of hyperthermia (3–5). In addition,
the adjuvant effect of chemotherapy seems to be less in locally advanced cases and toxicity of
thermoradiotherapy is mild (2, 5).We share the common opinion of Crezee et al. that the important
clinical consequence of hyperthermia and radiotherapy in the same center should not be based on
a single institutions’ experience. Hence, our decision to investigate the issue of the time interval in
our patient population (6). It was to our honest surprise that we found an absolute null effect of
the time interval with Hazard Ratio’s of a perfect 1.0 in 400 patients. In our discussion we thought
of potential explanations for the different findings between the two studies, including the potential
difference in temperatures achieved, as also pointed out by Crezee et al. (7).
A limitation of both our studies, besides the retrospective nature, is the long inclusion period;
1999–2014 for van Leeuwen et al. and 1996–2016 for our cohort. This makes both our analyses
subject to confounding factors, because of changes in interval times in different time periods. For
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TABLE 1 | Analysis of the effect of the time interval using univariate Cox analysis in patients groups divided over the quartiles of TRISE.
No of patients TRISE range (◦C) Temperature
range (
◦
C)
5-year local control (%) Number of local recurrences HR time interval 95% CI of HR p-value
94 0.54–2.93 37.54–39.93 60.6 38 1.00 0.99–1.01 0.758
93 2.94–3.46 39.94–40.46 69.3 24 1.00 0.99–1.01 0.769
93 3.47–3.86 40.47–40.86 69.0 24 1.00 0.99–1.01 0.250
93 3.87–5.16 40.87–42.16 72.5 20 1.00 0.99–1.01 0.624
example, in our cohort we observed longer waiting times between
RT and HT in earlier years vs. more recent years. Given the larger
number of patients in our cohort, we were able to analyze the
effect of the time interval per time period of 4–5 years, showing
no effect of the time interval for all time periods (1).
We agree with Crezee et al. that there is sufficient data
showing the effect of hyperthermia on DNA repair inhibition
at temperatures higher than 41◦C in preclinical models (8–
10), but not yet in patients (8). The median temperature
increase in our cohort was 40.5◦C, which seemed lower than
the cohort of van Leeuwen et al. Of note, the difference
in temperatures reported in both our cohorts, does not
automatically reflect a dose difference to the tumor, as there
are distinct differences in the treatment strategies regarding
guidance of SAR steering and temperature measurements (11,
12). Looking at our data, however, we observed a wide range
in the distribution of TRISE in our cohort, ranging from
0.54 to 5.16◦C. We hypothesized that in patients with a
high thermal dose, which are also present in our cohort,
the effect of the time interval on clinical outcome could be
present and could provide an independent confirmation of
the finding of van Leeuwen et al. Therefore, we performed
an additional analysis for the effect of the time interval on
clinical outcome in patients with a high thermal dose. For
this, we divided the cohort over the quartiles of TRISE and
using univariate Cox proportional hazard analysis, analyzed
the effect of the time interval on clinical outcome per TRISE
group. As stated by Crezee et al. the medium temperature
of their patient group is close to 41◦C, which is highly
comparable to the temperatures measured in patients of our
highest thermal dose group (40.87–42.16◦C). Strikingly, also
in the group of patients with the highest thermal dose, the
Hazard Ratio for Local Control remained 1.0 (95% CI 0.99–1.01;
p = 0.624) (Table 1). These results strongly indicate that—at
least in our cohort—the time interval also has not an effect on
outcome in patients with an average target temperature above
40.8◦C. Due to the retrospective design of both our studies,
without direct comparison with radiotherapy alone, nor with
chemoradiotherapy, the effectiveness of hyperthermia cannot be
directly proven. However, the strong correlation of thermal dose
with clinical outcome in our study is a strong indication of the
adjuvant effect of hyperthermia (13).
Clearly, the result of our additional analysis for the high
thermal dose group will not close the discussion on the
relevance of proper selection of the time interval between
RT and HT. The results of both cohort studies published
on the time interval question, strongly call for further future
research in a cooperative manner. We believe, that for the
benefit of future patients, further research should be performed
at two different levels. First at the clinical level, prospective
and uniform measurements and registration on all aspects of
hyperthermia treatments, including standardized thermal dose
and time interval measurements, should be performed across
multiple hyperthermia centers. Second, in vivo studies regarding
the exact working mechanisms of hyperthermia in patients, not
in models, are highly needed. We feel that the Overgaard paper is
an important paper, but it represents only a single experimental
setup in one tumor model, and can thus not be generalized to the
clinic (14).
Finally, fueled by similar level evidence showing conflicting
results, the controversy about the effect of the time interval
between RT and HT on clinical outcome will be ongoing.
We conclude that, during this period, patients with a
contraindication or refusing concurrent chemoradiotherapy,
can undergo thermoradiotherapy even with long time intervals
with the suggestion of no detriment in efficacy compared to
short intervals.
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